CEOs In Transition: Internal The Norm, But External Delivers Strong Returns
Executive Summary
CEO changes are underway across big pharma and biotech, marking a time of substantial leadership transition for the industry. New CEOs are usually insiders, but external hires appear to be more willing to implement change to improve shareholder returns, according to an analysis from Leerink.
You may also be interested in...
Novo Nordisk Names Jørgensen CEO As Sørensen Steps Down Early
Lars Rebien Sørensen is retiring as CEO of Novo Nordisk by the end of the year, with executive vice president and corporate development head Lars Fruergaard Jørgensen stepping up as his successor.
Lilly BioMedicines Head Ricks Tasked With Overseeing Growth Phase As Next CEO
Long-time CEO John Lechleiter, who led the company through a challenging period of enormous patent expirations, will step down at year's end.
Scangos Leaves Biogen Transformed And Transitioning
CEO George Scangos built Biogen into an innovative biotech, but his departure, coming as the company dusts itself off after a fall from glory, increased speculation Biogen could become a takeout target.